Fundz

Beam Therapeutics Inc.

Biotechnology, Healthcare, Health Care

Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting

Key facts

Employees
Unknown
Industries
Biotechnology, Healthcare, Health Care
Status
Public (BEAM)
Website
beamtx.com
LinkedIn
Company page

Recent activity at Beam Therapeutics Inc.

  • : Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
  • : SEC 8-K (1.02): On March 2, 2026, Beam Therapeutics Inc. and Bio Palette Co., Ltd. mutually terminated their License Agreement originally dated March 27, 2019, due to the planned dissolution of Bio Palette. This termination was formalized through a Termination Agreement executed on the same date. Prior to this termination, Bio Palette and Kobe University had also terminated their License Agreement, which activated a standby license for Beam Therapeutics under a Standby License Agreement effective February 9, 2026, thus ensuring that Beam retained rights to patents associated with base editing for certain treatments. The License Agreement was concluded in its entirety, releasing both parties from future claims and obligations regarding payments under the agreement. This development reflects significant strategic changes within the companies involved, particularly as it relates to their operations in the biotechnology field.
  • : SEC 8-K (1.01): On February 24, 2026, Beam Therapeutics Inc. entered into a Financing Agreement, establishing a senior secured term loan facility of up to $500 million. The Credit Facility includes an initial draw of $100 million on the Closing Date and allows for additional draws totaling $400 million upon achieving certain FDA approvals and revenue targets for the drug risto-cel. The facility matures on February 24, 2033, and bears an interest rate linked to the 3-month Secured Overnight Financing Rate plus a margin. Additionally, the agreement includes various covenants, including maintaining certain liquidity levels based on market capitalization, with all obligations secured by the Company's assets. The event date of February 24, 2026, marks a significant financial agreement aimed at bolstering the Company's operational funding and strategic initiatives.
  • : SEC 8-K (1.01): On February 9, 2026, Beam Therapeutics Inc. entered into a Standby License Agreement with Kobe University and Bio Palette Co., Ltd. to ensure continued access to certain patents in the event of termination of the existing Kobe-Bio Palette License. The agreement provides Beam with an exclusive license to the patents should specific termination conditions occur, compensating Kobe based on future payments owed to Bio Palette under a previously established license. This strategic move safeguards Beam's operations related to the licensed patents, crucial for its ongoing therapeutic developments.
  • : SEC 8-K (5.02):
  • : SEC 8-K (7.01): On January 11, 2026, the Company disclosed its progress in its base editing portfolio through a press release. This announcement includes the timeline for upcoming milestones and outlines key therapeutic applications of its technology. Furthermore, on January 12, 2026, the Company updated its corporate presentation in preparation for its participation at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, where it aims to present its ongoing clinical trials and future plans. The information provided is intended for investor awareness and is supplemented by Exhibits 99.1 and 99.2, detailing both the press release and slide deck, respectively.
  • : SEC 8-K (2.01): On December 8, 2025, Bristol-Myers Squibb Company (BMS) completed its acquisition of Orbital Therapeutics, Inc. (Orbital) under an Agreement and Plan of Merger dated October 10, 2025. Beam Therapeutics Inc. previously held 75 million shares of Orbital common stock, which represented a 17% ownership stake. At closing, these shares were converted into $255.1 million in cash, along with a potential additional $26.3 million upon the release of certain escrows. This acquisition is expected to positively influence Beam's cash runway, which will be detailed at the upcoming 2026 J.P. Morgan Healthcare Conference.
  • : SEC 8-K (2.01): On December 8, 2025, Bristol-Myers Squibb Company completed its acquisition of Orbital Therapeutics, Inc. as per an Agreement and Plan of Merger dated October 10, 2025. Beam Therapeutics Inc. previously held a 17% stake in Orbital, equating to 75 million shares, which were cancelled at closing. In exchange, Beam received $255.1 million in cash, along with potential additional cash of approximately $26.3 million, contingent upon certain escrow releases. This acquisition is expected to impact Beam's cash runway, with further updates anticipated during the 2026 J.P. Morgan Healthcare Conference.
  • : Beam Therapeutics Inc. Appoints Sravan K. Emany as Chief Financial Officer
  • : Beam Therapeutics Inc.

Beam Therapeutics Inc. funding history

DateRoundAmount
Mar 2019Venture$135.0M
Mar 2019Venture$83.6M
Aug 2018Venture$45.0M

Leadership

  • MICHAEL YI, Director
  • CAROLE HO, Director
  • MARK FISHMAN, Director
  • ROBERT NELSEN, Director
  • STEPHEN KNIGHT, Director
  • KRISTINA BUROW, Director
  • JOHN EVANS, Executive Officer, Director
  • MICHAEL YI, Director
  • CAROLE HO, Director
  • MARK FISHMAN, Director
  • ROBERT NELSEN, Director
  • STEPHEN KNIGHT, Director

Verified email and direct lines for Beam Therapeutics Inc.’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Employee benefit plans

Beam Therapeutics Inc. files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Beam Therapeutics Inc. in the news

Companies similar to Beam Therapeutics Inc.

About Beam Therapeutics Inc.: questions and answers

What does Beam Therapeutics Inc. do?

Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting

Has Beam Therapeutics Inc. raised funding?

Yes. Fundz has recorded 3 funding events for Beam Therapeutics Inc.. The most recent, $135.0M, was in Mar 2019.

What is the latest news on Beam Therapeutics Inc.?

On Sep 01, 2026, Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer

Is Beam Therapeutics Inc. a public company?

Yes. Beam Therapeutics Inc. is publicly traded under the ticker BEAM.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Beam Therapeutics Inc. across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.